Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selpercatinib PK in Hepatic Impairment
NCT05436912Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2018
- Primary completion
- Oct 2019
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, open-label trial of selpercatinib in non-small cell lung cancer (NSCLC), Medullary Thyroid Cancer (MTC) and thyroid cancer (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Concentration at 240 hours, Time to Reach Cmax at 240 hours and 6 more. Started Dec 2018; status: completed.
02
Drugs
selpercatinib
03
Conditions
non-small cell lung cancer (NSCLC)Medullary Thyroid Cancer (MTC)thyroid cancer
Beyond the preview
Go deeper on NCT05436912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05436912.